Clinical Trials Directory

Trials / Terminated

TerminatedNCT00073034

Study Evaluating EAA-090 in Adult Outpatients With Neuropathic Pain Associated With Diabetic Neuropathy

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of 3 Fixed Doses of EAA-090 in Adult Outpatients With Neuropathic Pain Associated With Diabetic Neuropathy

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
—
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

EAA-090 is being developed for the treatment of neuropathic pain associated with diabetic neuropathy. It is a selective antagonist that binds competitively to the glutamate site of the N-methyl-D-aspartate (NMDA) receptor. This study will assess the safety and efficacy of 3 fixed oral doses of EAA-090 compared with placebo in subjects with neuropathic pain associated with diabetic neuropathy.

Conditions

Interventions

TypeNameDescription
DRUGEAA-090

Timeline

Start date
2004-01-01
Primary completion
2004-12-01
Completion
2004-12-01
First posted
2003-11-18
Last updated
2013-02-21

Source: ClinicalTrials.gov record NCT00073034. Inclusion in this directory is not an endorsement.